Potential targets for pancreatic cancer immunotherapeutics.
about
Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Systemic Chemotherapy in Advanced Pancreatic CancerPancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesAllogeneic tumor cell vaccines: the promise and limitations in clinical trialsThe pancreas cancer microenvironmentA phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinomaRecent treatment advances and novel therapies in pancreas cancer: a review.Complex role for the immune system in initiation and progression of pancreatic cancer.Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy.Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors.CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas.Exchange protein directly activated by cAMP modulates regulatory T-cell-mediated immunosuppressionCarcinogenesis of pancreatic adenocarcinoma: precursor lesions.Risk factors and therapeutic targets in pancreatic cancer.Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.Advanced stage pancreatic cancer: novel therapeutic options.The need for effective pancreatic cancer detection and management: a biomarker-based strategy.Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses.Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination.Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters.Soluble MICA is elevated in pancreatic cancer: Results from a population based case-control study.Pancreatic cancer: Update on immunotherapies and algenpantucel-L.IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancerREG3β contributes to the immunosuppressive microenvironment of pancreatic cancer.The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells.A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes.P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma.Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene SO1861.Nanotechnologies in Pancreatic Cancer Therapy.Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report.
P2860
Q26747695-B94B119A-B3A7-402B-AD1C-63A907C0C534Q26750440-3F58795C-32DA-410B-8C88-ECB0463793DEQ26799714-CCFC81F0-E374-49F2-A94E-006721422E95Q26852333-58FB48EB-58A6-4E15-B994-70DB8185C1AFQ27026705-DA00318D-36BC-467B-9B8F-BFA4FA6A2AFCQ30412791-3E1D6C39-950C-4C2B-9C35-CB76212E16DFQ33625168-250CB1D5-BA2C-4C2C-B761-A625F99737B1Q34093784-F3FA898C-350A-462F-B71D-70424CF391E9Q34312466-8C8D7318-9960-4B8E-AFC2-5059ABDAD8CAQ36017958-D1567F65-F35B-4678-80DE-6B88B52B37D9Q36041701-7F786F6E-DE52-47AB-8034-90810E1866CBQ36569129-4A4EC512-09E6-4845-B017-E987C78B7AADQ36635113-D1013380-0E71-4835-985E-599E93F39C5BQ37291172-489CDF43-1AFD-44FE-B71A-40179852E6D4Q37317310-4C02BE91-5FB7-48E1-90BD-4339ED87BD6AQ37346107-3E592D15-50DB-499E-8FA8-8473AA09F178Q38221089-D1DE7038-A7DF-4758-A8C3-38D95BFE35D0Q38591066-5A120066-6B99-41C9-A6E7-A4148707E1E2Q38667672-9BDADFFE-8829-4265-8BE2-3CA245D89BCEQ38703429-9B9C7688-0AC9-4B57-A433-E26D76215F26Q38832639-90A4911E-F1B6-4094-80F3-EC6F050F0920Q39188023-73A31D86-B88A-4720-8FA0-0DE09D86AA40Q40215861-D12F8232-14CB-4913-AC19-EABA07278A07Q40261599-B7290FCA-9763-492F-8AC8-AE3E06CE54CDQ42015091-BBD7BDAC-CD32-41A8-8CDB-526100740A8EQ42796249-9A7F2079-4191-435D-B1B7-3F7B72F72E9FQ42927241-A7EBE470-9167-4C19-8C2E-6F8FA4B91F0CQ43214125-249C49EC-73A5-4B52-9974-E3D468C9CE5BQ44269708-34C449DC-4DE4-4372-8799-70AEA0845B34Q47101471-1C07BD08-C9B3-4725-AA50-B0E9D37D98C7Q48293480-446D4EBE-4E33-4271-BCC3-3C3FE9FD6A37Q50057949-EC70EFA3-9BEF-4941-AD19-27DFB79A9C9C
P2860
Potential targets for pancreatic cancer immunotherapeutics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Potential targets for pancreatic cancer immunotherapeutics.
@en
Potential targets for pancreatic cancer immunotherapeutics.
@nl
type
label
Potential targets for pancreatic cancer immunotherapeutics.
@en
Potential targets for pancreatic cancer immunotherapeutics.
@nl
prefLabel
Potential targets for pancreatic cancer immunotherapeutics.
@en
Potential targets for pancreatic cancer immunotherapeutics.
@nl
P2093
P2860
P356
P1433
P1476
Potential targets for pancreatic cancer immunotherapeutics.
@en
P2093
Lindzy F Dodson
Peter Goedegebuure
William G Hawkins
P2860
P304
P356
10.2217/IMT.11.10
P577
2011-04-01T00:00:00Z